Interestingly, we previously characterized iNKT cells in the context of ICP blockers in patients with melanoma and highlighted the crucial influence of the features of iNKT cells on the ability of patients to respond to anti-program cell death protein 1 (PD-1) therapy (41). This evidence concerns the gene PDCD1 and melanoma.